Venture Partners L.P.Longit... Net Worth

The estimated Net Worth of Venture Partners L.P.Longit... is at least $11.9 Milion dollars as of 22 November 2016. Venture Longit owns over 36,941 units of Corcept Therapeutics Inc stock worth over $6,402,662 and over the last 8 years Venture sold CORT stock worth over $5,546,625.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Longit CORT stock SEC Form 4 insiders trading

Venture has made over 2 trades of the Corcept Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Venture sold 36,941 units of CORT stock worth $345,029 on 22 November 2016.

The largest trade Venture's ever made was selling 544,100 units of Corcept Therapeutics Inc stock on 17 November 2016 worth over $5,201,596. On average, Venture trades about 193,680 units every 2 days since 2016. As of 22 November 2016 Venture still owns at least 180,103 units of Corcept Therapeutics Inc stock.

You can see the complete history of Venture Longit stock trades at the bottom of the page.

Insiders trading at Corcept Therapeutics Inc

Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson a Ventures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.

What does Corcept Therapeutics Inc do?

leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis

Complete history of Venture Longit stock trades at Corcept Therapeutics Inc

Corcept Therapeutics Inc executives and stock owners

Corcept Therapeutics Inc executives and other stock owners filed with the SEC include:

• Joseph Belanoff,
  President, Chief Executive Officer, Director
• Andreas Grauer,
  Chief Medical Officer
• Gary Robb,
  Chief Financial Officer, Secretary
• Sean Maduck,
  Senior Vice President - Commercial
• Dr. Joseph K. Belanoff M.D.,
  Co-Founder, Pres, CEO & Director
• Dr. Joseph K. Belanoff,
  Co-Founder, Pres, CEO & Director
• Dr. Hazel Hunt Ph.D.,
  Chief Scientific Officer
• Gary Charles Robb,
  Chief Bus. Officer & Sec.
• Sean Maduck,
  Chief Commercial Officer
• James Wilson,
  Independent Chairman of the Board
• Kimberly Park,
  Independent Director
• Daniel Swisher,
  Independent Director
• David Mahoney,
  Independent Director
• George Baker,
  Independent Director
• Gillian Cannon,
  Director
• Gregg Alton,
  Independent Director
• J.D. Lyon,
  Chief Accounting Officer
• Dr. William Guyer Pharm.D.,
  Chief Devel. Officer
• Donald E. Laferle,
  Sr. VP
• Amy Flood,
  Chief HR & Communications Officer
• Dr. Christopher Shayne James M.D.,
  Director of Investor Relations
• Joseph Douglas Lyon,
  Chief Accounting Officer
• Atabak Mokari,
  Chief Financial Officer
• Renee D Gala,
  Director
• G Leonard Jr Baker,
  Director
• Daniel Bradbury,
  Director
• Robert S Fishman,
  Chief Medical Officer
• Bakker Juliet Tammenoms,
  10% owner
• Venture Partners L.P.Longit...,
  
• Venture Partners Lp Longitu...,
  
• Steven Lo,
  VP Commercial Operations
• Biopharma Partners Ii Lpalt...,
  
• Allen Andersson,
  Director
• Ventures, Llc Paperboy,
  10% owner
• Edward Penhoet,
  Director
• Patrick G Enright,
  Director
• Caroline M Loewy,
  Chief Financial Officer
• Venture Partners Lp Longitu...,
  
• Hill Ventures Sutter,
  10% owner
• Biopharma Partners Ii Lpmar...,
  
• Biopharma Partners Ii Lpalt...,
  
• Alix Marduel,
  Director
• Alan F Schatzberg,
  Director
• David B Singer,
  Director
• Fred Kurland,
  Chief Financial Officer
• Joseph L Turner,
  Director
• Anne M Le Doux,
  VP & Controller
• Joseph C Jr Cook,
  Director
• William H Jr Younger,
  10% owner
• Robert L Roe,
  President and Secretary
• Hill Venturesbaker G Leonar...,
  Director
• Jeffrey W Bird,
  10% owner
• Tench Coxe,
  10% owner
• James N White,
  10% owner
• Gregory P Sands,
  10% owner
• Hill Venturesbaker G Leonar...,
  Director
• David L Anderson,
  10% owner
• Hill Ventureswhite James N ...,
  
• Michael L Speiser,
  10% owner
• James C Gaither,
  10% owner
• David E Sweet,
  10% owner
• Hill Venturesbird Jeffrey W...,
  
• James A Harper,
  Director
• Joshua M. Murray,
  
• Atabak Mokari,
  Chief Financial Officer
• William Guyer,
  Chief Development Officer
• Hazel Hunt,
  Chief Scientific Officer